Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.30 |
| ▸ | TUBB | P07437 | 1/20 | 0.30 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.30 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.30 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.30 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.30 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.30 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.30 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.30 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.30 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.30 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.30 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.30 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.30 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14814337 | 0.83 | TYMS (0.39) | TYMS | |
| SCHEMBL14814033 | 0.74 | HPGD (0.36) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL12467975 | 0.70 | PDPK1 (0.34) | — | |
| SCHEMBL12467651 | 0.70 | NTRK1 (0.38) | TYMS | |
| SCHEMBL12468012 | 0.67 | PDPK1 (0.34) | TYMS | |
| SCHEMBL12467608 | 0.64 | TYMS (0.34) | TYMS | |
| SCHEMBL16936129 | 0.62 | NTRK1 (0.55) | — | |
| SCHEMBL31207334 | 0.62 | KHK (0.35) | — | |
| SCHEMBL14746268 | 0.62 | JAK2 (0.36) | — | |
| SCHEMBL10333403 | 0.60 | PDE3B (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668184-B1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | PF MEDICAMENT (FR) | 2018-01-10 | — | — | EP | disclosed |
| EP-2877176-B1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING TRK | PF MEDICAMENT (FR) | 2017-04-26 | — | — | EP | disclosed |
| EP-2877177-B1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN | PF MEDICAMENT (FR) | 2016-10-26 | — | — | EP | disclosed |
| US-9428510-B2 | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing Trk | PIERRE FABRE MEDICAMENT (FR) | 2016-08-30 | — | — | US | disclosed |
| US-9381195-B2 | Derivatives of azaindazole or diazaindazole type for treating pain | PIERRE FABRE MEDICAMENT (FR) | 2016-07-05 | — | — | US | disclosed |
| US-20150266880-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING Trk | PIERRE FABRE MEDICAMENT (FR) | 2015-09-24 | — | — | US | disclosed |
| US-20150190394-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN | PIERRE FABRE MEDICAMENT (FR) | 2015-07-09 | — | — | US | disclosed |
| US-8883821-B2 | Substituted pyrazolo[3,4-b]pyridines as medicaments | PIERRE FABRE MEDICAMENT (FR) | 2014-11-11 | — | — | US | disclosed |
| EP-2689778-A1 | Derivatives of azaindoles or diazaindoles for treating pain | PIERRE FABRE MEDICAMENT (FR) | 2014-01-29 | — | — | EP | disclosed |
| EP-2689779-A1 | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk | PIERRE FABRE MEDICAMENT (FR) | 2014-01-29 | — | — | EP | disclosed |
| US-20130172360-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | PIERRE FABRE MEDICAMENT (FR) | 2013-07-04 | — | — | US | disclosed |
| US-20130085144-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | PIERRE FABRE MEDICAMENT (FR) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266880-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING Trk | TTK, NTRK1, NTRK3 | TYMS 798/4885TUBB4A 952/4885TUBB 444/4885 |
| US-20130085144-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | MAP2K5, MAP2K2, MAP2K3 | TYMS 848/4885TUBB4A 938/4885TUBB 405/4885 |
| US-20150190394-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN | SCN3A, ACHE, QDPR | TYMS 1910/4885TUBB4A 622/4885TUBB 267/4885 |
| US-20130172360-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | MAP2K5, MAP2K2, MAP2K3 | TYMS 848/4885TUBB4A 938/4885TUBB 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.